Question 1

What are the potential benefits of imatinib mesylate for my specific situation?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) clinical trial (NCT00171938). Contact the study team or your healthcare provider for specific answers.

Question 2

Are there any risks or side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) clinical trial (NCT00171938). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to other options available for my cancer?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) clinical trial (NCT00171938). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) clinical trial (NCT00171938). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my cancer progresses while on this treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) clinical trial (NCT00171938). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any additional tests or monitoring required during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) clinical trial (NCT00171938). Contact the study team or your healthcare provider for specific answers.

What this study is about